30230
Manuela Abreu, Sofia Barbosa, Ricardo Prata
46. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol. 1997;
11:S33‑7.
47. Fleishaker JC , Francom SF, Herman BD, et al. Lack of effect of reboxetine on cardiac depo-
larization. Clin Pharmacol Ther. 2001; 70:261‑9.
48. Hilton S, Jaber B, Ruch R. Moclobemide safety: monitoring a newly developed product in the
1990s. J Clin Psychopharmacol. 1995; 15:76S‑83S.
49. Downes MA, Whyte IM, Isbister GK. QTc abnormalities in deliberate self‑poisoning with
moclobemide. Intern Med J. 2005; 35:388‑91.
50. Carney RM, ENRICHD investigators. Enhancing recovery in coronary heart disease (ENRI-
CHD) study interventions: rationale and design. Psychosom Med. 2001; 63:747‑55.
51. Bekke‑Hansern S, Trockel M, Burg MM, et al. Depressive symptom dimensions and cardiac
prognosis following myocardial infarction: results from the ENRICHD clinical trial. Psycho-
som Med. 2012; 42: 51‑60.
52. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline Antidepressant Heart Attack Ran-
domized Trial (SADHEART) Group. Sertraline treatment of major depression in patients
with acute MI or unstable angina. JAMA. 2002; 288:701‑709.
53. Allen SN, John S, Shannon J, Ferrara J. Treatment of Depression in Patients on Anticoagula-
tion Therapy: Antidepressant‑Warfarin Drug Interactions. US Pharm. 2013; 38:23‑26.
54. Cochram K, Cavallari L, Shapiro N, et al. Bleeding incidence with concomitant use of antide-
pressants and warfarin. Ther Drug Monit. 2011; 33:433‑438.
55. Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of
selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial
infarction. CMAJ. 2011; 183:16.
56. Bachawati M. Anticoagulation and Psychotropic Medications. Curr Psychiatry Rep. 2010;
12:265‑271.
57. 57. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhi-
bitors in patients admitted with gastrointestinal haemorrhage: a multicenter retrospective
analysis. Aliment Pharmacol Ther. 2006; 23:937‑44.
58. Oyesanmi O, Kundel EJ, Monti DA, et al. Hematologic side effects of psychotropics. Psycho-
somatics. 1999; 40:414‑21.
59. Hirsh J, Fuster V, Ansell J et al. AHA/ACC Cientific Statement. American Heart Association/
American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation. 2003;
107: 1692‑1711.
60. Keeling D, Baglin T, Tait C, et al. British Committee for Standards in Haematology Guidelines
on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology 2011;
154: 311‑324.
